Antipsychotic Selection in Chronic Kidney Disease
Most antipsychotics are safe in CKD because they are fat-soluble, hepatically metabolized, and not dialyzable—use standard doses for most agents, but avoid amisulpride and reduce doses of sulpiride, paliperidone, and risperidone by 50% in severe renal impairment.
General Principles
The majority of antipsychotics do not require dose adjustment in kidney disease because they share favorable pharmacokinetic properties 1, 2:
- Fat soluble with high lipophilicity
- Hepatically metabolized rather than renally excreted
- Not removed by dialysis (including hemodialysis)
- Highly protein-bound (though protein binding may be impaired in end-stage kidney disease, potentially increasing free drug levels)
Specific Antipsychotic Recommendations
Safe Without Dose Adjustment
These agents can be used at standard doses across all stages of CKD 3, 4, 2:
- Aripiprazole (oral and long-acting injectable)
- Ziprasidone
- Olanzapine
- Quetiapine
- Haloperidol
- Clozapine
Requires Dose Reduction
Amisulpride: Contraindicated or requires substantial dose reduction—this is the primary antipsychotic to avoid in renal failure 3, 5.
Sulpiride: Should be avoided or used with extreme caution 5.
Paliperidone: Reduce to 50% of conventional dose in severe CKD. Long-acting injectable paliperidone is well-tolerated but requires dose adjustment 3.
Risperidone: While generally safe, consider modest dose reduction in severe renal impairment. Long-acting injectable risperidone appears well-tolerated without adjustment 3.
Hemodialysis-Specific Considerations
For patients on hemodialysis, the evidence supports 3:
- Multiple daily dosing may be preferable for oral aripiprazole, ziprasidone, olanzapine, and risperidone
- Timing relative to dialysis sessions generally does not matter for most antipsychotics since they are not dialyzable
- Maximum dosing rule: Use no more than two-thirds of the standard maximum dose as your ceiling 1
- Monitor drug levels monthly after initiation and whenever adjusting doses 1
Critical Monitoring Parameters
When prescribing antipsychotics in CKD 6, 7:
- Anticholinergic burden: Avoid quetiapine if possible in patients already on multiple anticholinergic medications (44% of dialysis patients have ACB scores ≥3)
- Protein binding alterations: In end-stage renal disease, impaired protein binding increases free drug levels—start low and titrate slowly 1
- Drug-drug interactions: CYP-3A4 remains relatively unaltered during hemodialysis, so standard interaction profiles apply 3
- Bowel absorption: May be impaired in hemodialysis patients, affecting oral bioavailability 3
Common Pitfalls to Avoid
Do not assume all antipsychotics need dose adjustment—this leads to under-treatment. Most are safe at standard doses.
Avoid diazepam and benzodiazepines with active metabolites—these accumulate in renal failure 1.
Do not discontinue antipsychotics during dialysis sessions—they are not removed by dialysis 3, 2.
Watch for anticholinergic polypharmacy—quetiapine combined with bladder antimuscarinics or antihistamines significantly increases anticholinergic burden 6.
Beware of volume of distribution changes—hemodialysis affects Vd in complex ways that don't always correlate with creatinine clearance 3.